

# Matthias Scheffler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6717105/publications.pdf>

Version: 2024-02-01

81  
papers

2,883  
citations

186265

28  
h-index

175258

52  
g-index

83  
all docs

83  
docs citations

83  
times ranked

4523  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 4837-4847.   | 7.0  | 223       |
| 2  | K-ras Mutation Subtypes in NSCLC and Associated Co-occurring Mutations in Other Oncogenic Pathways. <i>Journal of Thoracic Oncology</i> , 2019, 14, 606-616.  | 1.1  | 178       |
| 3  | Early Prediction of Nonprogression in Advanced Nonâ€“Small-Cell Lung Cancer Treated With Erlotinib By Using [ <sup>18</sup> F]Fluorodeoxyglucose and [ <sup>18</sup> F]Fluorothymidine Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2011, 29, 1701-1708. | 1.6  | 170       |
| 4  | Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. <i>Clinical Pharmacokinetics</i> , 2011, 50, 551-603.  | 3.5  | 163       |
| 5  | Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1451-1457.   | 1.1  | 141       |
| 6  | Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 2068-2075.   | 1.2  | 132       |
| 7  | Clinical and Pathological Characteristics of <i>KEAP1</i> - and <i>NFE2L2</i> -Mutated Nonâ€“Small Cell Lung Carcinoma (NSCLC). <i>Clinical Cancer Research</i> , 2018, 24, 3087-3096.  | 7.0  | 116       |
| 8  | Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. <i>PLoS ONE</i> , 2011, 6, e19601.  | 2.5  | 107       |
| 9  | Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. <i>Nature Communications</i> , 2018, 9, 4655.   | 12.8 | 107       |
| 10 | <i>PIK3CA</i> mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies. <i>Oncotarget</i> , 2015, 6, 1315-1326.  | 1.8  | 105       |
| 11 | Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. <i>Clinical Pharmacokinetics</i> , 2011, 50, 371-403.  | 3.5  | 95        |
| 12 | PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. <i>Oncolmmunology</i> , 2016, 5, e1131379.   | 4.6  | 94        |
| 13 | Cell-Autonomous and Nonâ€“Cell-Autonomous Mechanisms of Transformation by Amplified <i>FGFR1</i> in Lung Cancer. <i>Cancer Discovery</i> , 2014, 4, 246-257.  | 9.4  | 93        |
| 14 | Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1049-1057.  | 1.1  | 85        |
| 15 | <i>ROS1</i> rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. <i>Oncotarget</i> , 2015, 6, 10577-10585.  | 1.8  | 85        |
| 16 | Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic <i>ROS1</i> -Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1266-1276.   | 1.1  | 78        |
| 17 | Association of <i>STK11/LKB1</i> genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 102-102.                             | 1.6  | 72        |
| 18 | Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Nonâ€“Small Cell Lung Cancer Using <sup>18</sup> F-FDG and <sup>3</sup> â€“Deoxy- <sup>3</sup> â€“-18F-Fluorothymidine PET. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1871-1877.                 | 5.0  | 65        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. <i>Journal of Thoracic Oncology</i> , 2016, 11, 122-127.  | 1.1 | 65        |
| 20 | Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. <i>Oncologist</i> , 2015, 20, 1167-1174.   | 3.7 | 59        |
| 21 | Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 249-258.  | 6.4 | 49        |
| 22 | Tumor Lesion Glycolysis and Tumor Lesion Proliferation for Response Prediction and Prognostic Differentiation in Patients With Advanced Non-Small Cell Lung Cancer Treated With Erlotinib. <i>Clinical Nuclear Medicine</i> , 2012, 37, 1058-1064.  | 1.3 | 47        |
| 23 | Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1117-1127.           | 6.4 | 43        |
| 24 | Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 572-582.  | 1.1 | 38        |
| 25 | Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 76-88.  | 1.1 | 37        |
| 26 | Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib. <i>PLoS ONE</i> , 2013, 8, e53081.   | 2.5 | 36        |
| 27 | Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient. <i>Journal of Thoracic Oncology</i> , 2015, 10, e40-e43. | 1.1 | 33        |
| 28 | Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. <i>European Journal of Cancer</i> , 2022, 167, 142-148.  | 2.8 | 32        |
| 29 | ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor. <i>Npj Precision Oncology</i> , 2017, 1, 4.  | 5.4 | 30        |
| 30 | Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2017, 23, 962-973.  | 7.0 | 29        |
| 31 | Treatment Monitoring of Immunotherapy and Targeted Therapy Using <sup>18</sup> F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. <i>Journal of Nuclear Medicine</i> , 2021, 62, 464-470.   | 5.0 | 25        |
| 32 | Fully Automated MR Detection and Segmentation of Brain Metastases in Non-Small Cell Lung Cancer Using Deep Learning. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 1608-1622.  | 3.4 | 25        |
| 33 | On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma. <i>Lung Cancer</i> , 2021, 160, 152-165.  | 2.0 | 24        |
| 34 | Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2010, 5, 407-409.  | 1.1 | 22        |
| 35 | Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.  | 3.0 | 17        |
| 36 | MA07.05 EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results. <i>Journal of Thoracic Oncology</i> , 2017, 12, S379-S380.   | 1.1 | 15        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET. <i>Lung Cancer</i> , 2012, 77, 617-620. | 2.0 | 14        |
| 38 | Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. <i>Cancer Medicine</i> , 2020, 9, 4991-5007.   | 2.8 | 14        |
| 39 | Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib. <i>Journal of Thoracic Oncology</i> , 2015, 10, 84-92.  | 1.1 | 12        |
| 40 | Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET. <i>Clinical Lung Cancer</i> , 2019, 20, e148-e151.                                 | 2.6 | 11        |
| 41 | Phase 1 and phase 2a, first-in-human (FIH) study, of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS3149-TPS3149.                                   | 1.6 | 11        |
| 42 | Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. <i>Npj Precision Oncology</i> , 2021, 5, 102.  | 5.4 | 11        |
| 43 | Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations. <i>Lung Cancer</i> , 2020, 144, 40-48.   | 2.0 | 9         |
| 44 | A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients. <i>AAPS Journal</i> , 2015, 17, 1483-1491.   | 4.4 | 7         |
| 45 | Survival following implementation of next-generation sequencing in routine diagnostics of advanced lung cancer: Results of the German Network Genomic Medicine.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9085-9085.                   | 1.6 | 7         |
| 46 | Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma. <i>Future Oncology</i> , 2021, 17, 3965-3976.  | 2.4 | 6         |
| 47 | Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications. <i>Lung Cancer</i> , 2022, 168, 10-20.   | 2.0 | 6         |
| 48 | Genetic heterogeneity of KRAS-mutated NSCLC: Co-occurrence of potentially targetable aberrations and evolutionary background.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9018-9018.   | 1.6 | 5         |
| 49 | Acquired resistance to MET inhibition in MET driven NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9030-9030.  | 1.6 | 5         |
| 50 | Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma. <i>Lung Cancer</i> , 2019, 133, 20-22.   | 2.0 | 4         |
| 51 | Treatment monitoring of immunotherapy and targeted therapy using FET PET in patients with melanoma and lung cancer brain metastases: Initial experiences.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13525-e13525.                     | 1.6 | 3         |
| 52 | Reproducibility of dynamic contrast enhanced MRI derived transfer coefficient K <sub>trans</sub> in lung cancer. <i>PLoS ONE</i> , 2022, 17, e0265056.  | 2.5 | 3         |
| 53 | Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.   | 3.0 | 2         |
| 54 | Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20682-e20682.  | 1.6 | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Crizotinib in <i>ROS1</i> -rearranged lung cancer (EUCROSS): Updated overall survival.. Journal of Clinical Oncology, 2022, 40, 9078-9078.  | 1.6 | 2         |
| 56 | Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center. Lung Cancer, 2017, 108, 134-139.   | 2.0 | 1         |
| 57 | 32. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING AMINO ACID PET IN PATIENTS WITH BRAIN METASTASES. Neuro-Oncology Advances, 2020, 2, ii5-ii6.   | 0.7 | 1         |
| 58 | <i>KEAP1</i> -mutations in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8097-8097.  | 1.6 | 1         |
| 59 | Clinical and molecular characteristics of non-small cell lung cancer in patients harboring CTNNB1 mutations.. Journal of Clinical Oncology, 2015, 33, 8098-8098.  | 1.6 | 1         |
| 60 | The network genomic medicine cost reimbursement model for implementation of comprehensive lung cancer genotyping in clinical routine.. Journal of Clinical Oncology, 2015, 33, e12556-e12556.   | 1.6 | 1         |
| 61 | SORAVE: A phase I trial to evaluate safety and efficacy of combination therapy with everolimus and sorafenib.. Journal of Clinical Oncology, 2015, 33, 2550-2550.   | 1.6 | 1         |
| 62 | EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer – preliminary data on safety and tolerability.. Journal of Clinical Oncology, 2019, 37, e20577-e20577. | 1.6 | 1         |
| 63 | Reply to M. Quintela-Fandino et al. Journal of Clinical Oncology, 2011, 29, 3718-3719.  | 1.6 | 0         |
| 64 | P2.03b-076 MAP2K1 Mutations in NSCLC: Clinical Presentation and Co-Occurrence of Additional Genetic Aberrations. Journal of Thoracic Oncology, 2017, 12, S982.  | 1.1 | 0         |
| 65 | P2.03b-028 Improved Overall Survival Following Implementation of NGS in Routine Diagnostics of Advanced Lung Cancer in Germany: Results of the NGM. Journal of Thoracic Oncology, 2017, 12, S950-S951.  | 1.1 | 0         |
| 66 | P2.03b-036 Analysis of Potentially Targetable Mutations in 821 Patients with Squamous cell Lung Cancer Undergoing Routine NGS-Based Molecular Diagnostics. Journal of Thoracic Oncology, 2017, 12, S956-S957.   | 1.1 | 0         |
| 67 | YI01b.02 Expectations from a Young Investigator. Journal of Thoracic Oncology, 2017, 12, S226-S227.   | 1.1 | 0         |
| 68 | OTHR-14. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING FET PET IN PATIENTS WITH MELANOMA AND LUNG CANCER BRAIN METASTASES: INITIAL EXPERIENCES. Neuro-Oncology Advances, 2019, 1, i21-i21.   | 0.7 | 0         |
| 69 | <i>KEAP1</i> mutations in squamous cell lung cancer.. Journal of Clinical Oncology, 2021, 39, e21098-e21098.  | 1.6 | 0         |
| 70 | Abstract 956: Elucidating the mechanisms of acquired resistance in lung adenocarcinomas. , 2014, , .  |     | 0         |
| 71 | Genetic variability and clinical presentation of patients with non-small cell lung cancer (NSCLC) harboring <i>MET</i> -amplifications.. Journal of Clinical Oncology, 2015, 33, 8088-8088.   | 1.6 | 0         |
| 72 | <i>ROS1</i> rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitive impact and genetic variability.. Journal of Clinical Oncology, 2015, 33, 8066-8066.   | 1.6 | 0         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Abstract 752: Elucidating the mechanisms of acquired resistance in lung adenocarcinomas. , 2015, , .  |     | 0         |
| 74 | Economic burden of clinical trials in lung cancer in a German comprehensive cancer center.. Journal of Clinical Oncology, 2016, 34, e18278-e18278.  | 1.6 | 0         |
| 75 | Fibroblast kinase 1-3 inhibitor BGJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study: Evaluation of tumor tissue and response at a single center.. Journal of Clinical Oncology, 2017, 35, e20664-e20664. | 1.6 | 0         |
| 76 | Expanded molecular routine testing for targetable mutations in non-small cell lung cancer to reveal frequent co-occurring mutations.. Journal of Clinical Oncology, 2017, 35, e20596-e20596.  | 1.6 | 0         |
| 77 | Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring <i>MAP2K1</i> mutations.. Journal of Clinical Oncology, 2017, 35, e20059-e20059.   | 1.6 | 0         |
| 78 | Molecular panel sequencing of pre-treatment samples to reveal mechanisms of innate resistance to 3rd generation EGFR TKI treatment in T790M-positive NSCLC patients.. Journal of Clinical Oncology, 2017, 35, 9041-9041.                                    | 1.6 | 0         |
| 79 | Abstract CT255: EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant NSCLC. , 2020, , .  |     | 0         |
| 80 | Screening of FGFR patients for FGFR directed clinical trials in Network Genomic Medicine (NGM): Real-world data.. Journal of Clinical Oncology, 2022, 40, e21013-e21013.  | 1.6 | 0         |
| 81 | Metastatic patterns plus clinical and molecular characteristics of <i>ROS1</i> aberrations in non-small cell lung cancer patients without rearrangements.. Journal of Clinical Oncology, 2022, 40, e21117-e21117.   | 1.6 | 0         |